

# ACTA MEDICINAE 2/2013 Kompletní literatura

## ALERGOLOGIE, PNEUMOLOGIE

- 2 **Alergologie a klinická imunologie v roce 2013**  
prof. MUDr. Václav Špičák, CSc. IMMUNO-FLOW, s. r. o., Praha, Česká iniciativa pro astma, o. p. s.
- 2 **Patogeneze chronické obstrukční plicní nemoci a možnosti protizánětlivé léčby**  
MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha
- 3 **Atopický ekzém – co nového v léčbě?**  
Prim. MUDr. Štěpánka Čapková Dermatologické oddělení pro děti, FN Motol, Praha  
RNDr. Dana Nováková Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol, Praha
- 3 **Kontaktní ekzém – kontaktní alergen**  
doc. MUDr. Eliška Dastychová, CSc. I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně
- 4 **Léčba atopické dermatitidy v přehledu**  
MUDr. Radek Litvík Kožní oddělení FN Ostrava
- 4 **Role vitamínu D u chronických zánětlivých onemocnění**  
MUDr. Jana Čepová, Ph.D., MBA | MUDr. Margareta Beyerová | Ing. Eva Klapková, Ph.D. | Ing. Marta Pechová |  
prof. MUDr. Richard Průša, CSc. Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha
- 4 **Doporučené postupy v léčbě astmatu bronchiale**  
MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
- 5 **Rinosinusitidy: od praktického lékaře do specializované péče ORL nebo alergologie?**  
MUDr. Jan Pokorný, CSc. DG Centrum Ostrava, ORL
- 5 **Využití salinických roztoků v léčbě onemocnění horních cest dýchacích**  
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 5 **Kardiovaskulární bezpečnost indakaterolu v léčbě chronické obstrukční plicní nemoci**  
Prim. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie Nemocnice Na Bulovce a 3. LF UK Praha
- 6 **Novinky v léčbě karcinomu plic**  
prof. MUDr. Jana Skříčková, CSc. | MUDr. Marcela Tomíšková | MUDr. Bohdan Kadlec | MUDr. Lenka Jakubíková, Ph.D. |  
MUDr. Jana Špaldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno  
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz LF a PF MU Brno
- 7 **Chronická obstrukční plicní nemoc**  
MUDr. Lucie Cwíková Městská nemocnice Ostrava-Fifejdy
- 7 **Flutikazon furoát v léčbě alergické rýmy**  
MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň
- 7 **Léčba pacienta IFN-β-1b (Betaferonem)**  
MUDr. Magdaléna Hladíková, Ph.D. Neurologická klinika LF MU a FN Brno
- 7 **Využití certolizumab pegolu v léčbě aktivní revmatoidní artritidy**  
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň
- 8 **Účinná léčba abataceptem v první linii u pacientky s diabetem mellitem I. typu a s revmatoidní artritidou**  
MUDr. Petr Kopsa Revmatologické a rehabilitační oddělení Thomayerovy nemocnice, Praha
- 8 **Subkutánní interferon beta-1a v léčbě roztroušené sklerózy**  
MUDr. Iva Okáčová | doc. MUDr. Pavel Štourač, Ph.D. Neurologická klinika LF MU a FN Brno, CEITEC – Středoevropský technologický institut MU Brno
- 8 **Systémová léčba osteolýzy indukované nádorem**  
MUDr. Simona Paulíková | prof. MUDr. Jiří Petera Ph.D. | MUDr. Adam Paulík  
LF UK a Klinika onkologie a radioterapie FN Hradec Králové
- 9 **Antitrombotická léčba – léčba apixabanem**  
MUDr. Hynek Poul Oddělení hematologie a transfuziologie Nemocnice Pelhřimov, p. o.
- 9 **Novinky ve fekální bakterioterapii**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

# Alergologie a klinická imunologie v roce 2013

prof. MUDr. Václav Špičák, CSc. IMMUNO-FLOW, s. r. o., Praha, Česká iniciativa pro astma, o. p. s.

- 1 **Blahoš, J. – Ticháček, B.:** STOROČENKA, historie České lékařské společnosti J. E. Purkyně, ČLS JEP, 2005.
- 2 **Špičák, V.:** Genetika alergie. In: Petrů, V.: *Dětská alergologie*, Mladá fronta, 2012, s. 35.
- 3 **Špičák, V.:** Etiopatogeneze alergie. In: Petrů, V.: *Dětská alergologie*, Mladá fronta, 2012, s. 66.
- 4 **Bochner, B. B., et al.:** Advances in mechanisms of allergy and clinical immunology in 2012. *J Allergy Clin Immunol*, 2013, v tisku.
- 5 **Kauffmann, F. – Demenais, F.:** Gene-environment interactions in asthma and allergic diseases: Challenges and perspectives. *JACI*, 2012, 130, s. 1229–1240.
- 6 **Yang, I. V. – Schwarz, D. A.:** Epigenetic mechanisms and the development of asthma. *JACI*, 2012, 130, s. 1243–1255.
- 7 **Choy, D. F., et al.:** Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. *The Journal of Immunology*, 2011, 186, s. 1861–1869.
- 8 **Woodruff, P. C., et al.:** T-helper type 2-driven inflammation defines major subphenotypes of asthma. *American J of Respiratory and Critical Care Medicine*, 2009, 180, s. 388–395.
- 9 **Von Gunten, S., et al.:** Update in clinical allergy and immunology. *Allergy*, 2012, 67, s. 1491–1500.
- 10 **Soyer, O. U., et al.:** Mechanisms of peripheral tolerance to allergens. *Allergy*, 2013, 68, s. 161–170.
- 11 **Špičák, V.:** České stopy v alergologii. *Alergie*, 2012, 14, s. 246–250.

## Patogeneze chronické obstrukční plicní nemoci a možnosti protizánětlivé léčby

MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha

- 1 **Bateman, E. D. – Rabe, K. F. – Calverley, P. M. A. – Goehring, U. M. – Brose, M. – Bredenbroker, D., et al.:** Roflumilast with long-acting + 2-agonists for COPD: influence of exacerbation history. *European Respiratory Journal*, 2011, 38, s. 553–560.
- 2 **Bourdin, A. – Burgel, P.-R. – Chanez, P. – Garcia, G. – Perez, T. – Roche, N.:** Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. *European Respiratory Review*, 2009, 18, s. 198–212.
- 3 **Burgel, P.-R. – Bourdin, A. – Chanez, P. – Chabot, F. – Chaouat, A. – Chinet, T., et al.:** Update on the roles of distal airways in COPD. *European Respiratory Review*, 2011, 20, s. 7–22.
- 4 **Calverley, P. – Rabe, K. – Goehring, U. – Kristiansen, S. – Fabbri, L. – Martinez, F., et al.:** Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*, 2009, 374, s. 685–694.
- 5 **Celli, B. R. – MacNee, W. – Agusti, A. – Anzueto, A. – Berg, B. – Buist, A. S., et al.:** Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. *Eur Respir J*, 2004, 23, s. 932–946.
- 6 **Fabbri, L. – Calverley, P. – Izquierdo-Alonso, J. – Bundschuh, D. – Brose, M. – Martinez, F., et al.:** Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. *Lancet*, 2009, 374, s. 695–703.
- 7 **Gibson, G.:** Pulmonary hyperinflation a clinical overview. *Eur Respir J*, 1996, 9, s. 2640–2649.
- 8 **Gibson, G.:** Lung volumes and elasticity. *Clin Chest Med*, 2001, 22, s. 623–635.
- 9 **Grootendorst, D. C. – Gauw, S. A. – Verhoosel, R. M. – Sterk, P. J. – Hospers, J. J. – Bredenbroker, D., et al.:** Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. *Torax*, 2007, 62, s. 1081–1087.
- 10 **Hatzelmann, A. – Morcillo, E. – Lungarella, G. – Adnot, S. – Sanjar, S. – Beume, R., et al.:** The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. *Pulm Pharmacol Ther*, 2010, 23, s. 235–256.
- 11 **Mclvor, R. A.:** Future options for disease intervention: Important advances in phosphodiesterase 4 inhibitors. *European Respiratory Review*, 2007, 16, s. 105–112.
- 12 **O'Donnell, D. – Laveneziana, P.:** Physiology and consequences of lung hyperinflation in COPD. *Eur Respir Rev*, 2006, 15, s. 61–67.
- 13 **O'Donnell, D. – Laveneziana, P.:** The clinical importance of dynamic lung hyperinflation in COPD. *COPD*, 2006, 3, s. 219–232.
- 14 **O'Donnell, D. – Webb, K.:** Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. *Am Rev Respir Dis*, 1993, 148, s. 1351–1357.
- 15 **O'Donnell, D. E. – Bredenbroker, D. – Brose, M. – Webb, K. A.:** Physiological effects of roflumilast at rest and during exercise in COPD. *European Respiratory Journal*, 2012, 39, s. 1104–1112.
- 16 **Rabe, K.:** Roflumilast for the treatment of chronic obstructive pulmonary disease. *Expert Rev Resp Med*, 2010, 4, s. 543–555.
- 17 **Rabe, K. – Hurd, S. – Anzueto, A. – Barnes, P. – Buist, S. – Calverley, P., et al.:** Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*, 2007, 176, s. 532–555.
- 18 **Suissa, S. – Barnes, P.:** Inhaled corticosteroids in COPD: the case against. *Eur Respir J*, 2009, 34, s. 13–16.
- 19 **White, W. B., et al.:** *ATS 2011*, P E71.
- 20 **Wouters, E. F. M., et al.:** *J Clin Endocrinol Metab*, 2012, 97 (9), s. E1720–E1725.

# Atopický ekzém – co nového v léčbě?

Prim. MUDr. Štěpánka Čapková Dermatologické oddělení pro děti, FN Motol, Praha

RNDr. Dana Nováková Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol, Praha

- 1 Paller, A. S. – Mancini, A. J.: Hurwitz clinical pediatric dermatology. Fourth edition multimedia on line. Elsevier Saunders, 2011, s. 624.
- 2 Bieber, T. – Cork, M. – Reitamo, S.: Atopic dermatitis: a candidate for disease-modifying strategy. *Allergy*, 2012, 67, s. 969–975.
- 3 Benáková, N.: Atopická dermatitida v roce 2009. *Čes-slov Derm*, 2009, 84, s. 65–86.
- 4 Baron, S. E. – Cohen, S. N. – Archer, C. B.: Guidance on the diagnosis and clinical management of atopic eczema. *Clinical and Experimental Dermatology*, 2012, 37, s. 7–12.
- 5 Akdis, C. A. – Akdis, M. – Bieber, T., et al.: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology / American Academy of Allergy, Asthma and Immunology / PRACTALL Consensus Report. *J Allergy Clin Immunol*, 2006, 118, s. 152–169.
- 6 Ring, J. – Alomar, A. – Bieber, T., et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. *JEADV*, 2012, 26, s. 1045–1060.
- 7 Ring, J. – Alomar, A. – Bieber, T., et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *JEADV*, 2012, 26, s. 1176–1193.
- 8 Hoare, C. – Li Wan Po, A. – Williams, H.: *Systematic review of treatments for atopic eczema*. Health Technol Assess, 2000.
- 9 Darsow, U. – Wollenberg, A. – Simon, D., et al.: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. *JEADV*, 2010, 24, s. 317–328.

# Kontaktní ekzém – kontaktní alergie

doc. MUDr. Eliška Dastychová, CSc. I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně

- 1 Beckmann, B. – Ippen, H.: Teebaum-Öl. *Dermatose*, 1998, 46, s. 120–124.
- 2 Camarasa, J. G.: Contact dermatitis to ketoprofen. *Contact Dermatitis*, 1985, 12, s. 120–122.
- 3 Cavalier, C. – Fousseau, J.: Kontaktallergie gegen Metalle und deren Salze. Teil II. Nickel, Kobalt, Quecksilber und Palladium. *Dermatosen in Beruf und Umwelt*, 1995, 43, s. 152–162.
- 4 Coz, Ch. J. L. – Bottlaender, A. – Scrivener, J. N. – Santinelli, F. – Criber, B. J. – Heid, E. – Grosshans, E. M.: Photocontact dermatitis from ketoprofen and tiaprofenic acid: Cross-reactivity study in 12 consecutive patients. *Contact Dermatitis*, 1998, 38, s. 245–252.
- 5 Dastychová, E.: Nežádoucí účinky extern obsahujících ketoprofen. *Čs Derm*, 2000, 75, s. 51–55.
- 6 Doms-Goossens, A. – Andersen, K. E. – Brandao, F. M. – Bruynzeel, D. – Burrows, D. – Camarasa, J. – Ducombs, G. – Frosch, P. – Hanuksela, M. – Lachapelle, J. M. – Lathi, A. – Menné, A. – Wahlberg, J. E. – Wilkinson, J. D.: Corticosteroid contact allergy: an EECDRG multicentre study. *Contact Dermatitis*, 1996, 35, s. 40–44.
- 7 Fousseau, J.: An epidemiological study of contact allergy to 5-chloro-3-methylisothiazolone 3-methyl-isothiazolone in Strasbourg. *Contact Dermatitis*, 1990, 22, s. 68–70.
- 8 Gebhardt, M. – Wollina, U.: Kutane Nebenwirkungen nichtsteroidaler Antiflogistika. *Z Rheumatol*, 1995, 54, s. 405–412.
- 9 Greig, J. E. – Thoo, S. L. – Carson, Ch. F. – Riley, T. V.: Allergic contact dermatitis following use of a tea tree oil hand-wash not due to tea tree oil. *Contact Dermatitis*, 1999, 41, s. 354.
- 10 Groot, A. C.: Airborne allergic contact dermatitis from Tea Tree Oil. *Contact Dermatitis*, 1996, 35, s. 304–305.
- 11 Groot, A. C. – Frosch, P. J.: Averse reactions to fragrances. A clinical review. *Contact Dermatitis*, 1997, 36, s. 57–86.
- 12 Kränke B.: Allergisierende Potenz von Teebaum-Öl. *Hautarzt*, 1997, 48, s. 203–204.
- 13 Lehmann, P. – Werner, A. – Bäuerle, G. – Breit, R. – Frosch, P. – Fuchs, T. – Günter, G. – Neumann, N. J. – Schaller, J. – Schulze-Dirks, A. – Vieluf, D. – Wilhelm, P.: Coricosteroid contact dermatitis: Result of a multicenter study from the German Contact Allergy Group. *Dermatosen*, 1997, 45, s. 116–120.
- 14 Mozzanica, N. – Pigatto, P. D.: Contact and photocontact allergy to ketoprofen: Clinical and experimental study. *Contact Dermatitis*, 1990, 23, s. 336–340.
- 15 Rietschel, R. L. – Fowler, J. F., jr.: *Fischer's Contact dermatitis*, 2008, s. 275–278, 287–288, 670–681, 393–404.
- 16 Semrádová, V. – Dastychová, E. – Navrátilová, Z.: Kontaktní alergie na kortikosteroidy. *Čs Derm*, 1999, 74, s. 113–117.
- 17 Semrádová, V. – Dastychová, E.: Polyvalent contact allergy to corticosteroids: A report of two cases. *JEADV*, 2001, 15, s. 350–353.
- 18 Urbanček, S.: Alergény štandardnej série. In: Urbanček, S. – Dastychová, E. – Buchvald, D. – Vocilková, A.: *Kontaktné alergény v pracovnom a životnom prostredí*, 2006, s. 41–73.
- 19 Uter, W. – Lessmann, H. – Geier, J. – Schnuch, A.: Contact allergy to ingredients of hair cosmetics in female hairdressers and clients — an 8-year analysis of IVDK data. *Contact Dermatitis*, 2003, 49, s. 236–240.
- 20 Uter, W. – Hegewald, J. – Aberer, W. – Ayala, F. – Bircher, A. J. – Brach, J. – Coenraads, P.-J. – Schuttellar, M.-L. A. – Elsner, P. – Fartasch, M. – Mahler, V. – Fortina, A. B. – Frosch, P. J. – Fusch, T. – Johansen, J. D. – Menné, T. – Jolanou, R. – Kręcisz, B. – Kiec-Swierczynka, M. – Larese, F. – Orton, D. – Peserico, A. – Rantanen, T. – Schnuch, A.: The European standard series in 9 European countries, 2002/2003 — First results of the European Surveillance System on Contact Allergies. *Contact dermatitis*, 2005, 53, s. 136–145.
- 21 Wilkinson, S. M.: Hypersensitivity to topical corticosteroids. *Clin Exp Derm*, 1994, 19, s. 1–11.
- 22 Wilkinson, S. M. – Hollis, S. – Beck, M. H.: Reaktionen auf andere Kortikosteroide bei Patienten mit allergischer Kontaktdermatitis infolge Hydrocortison. *Z Hautkr*, 1995, 70, s. 368–372.
- 23 The ESSCA Writing Group: The European Surveillance System of Contact Allergies (ESSCA): results of patch rating the standard series, 2004. *JEADV*, 2008, 22, s. 174–181.

# Léčba atopické dermatitidy v přehledu

MUDr. Radek Litvik Kožní oddělení FN Ostrava

- 1 Litvik, R.: Atopický ekzém dospělého věku. In: *Dermatologie v kazuistikách*. Praha, Mladá fronta, 2008, s. 187–194.
- 2 Litvik, R.: Úloha kožní bariéry u atopické dermatitidy. *Farmakoterapie*, 2008, s. 11–21.
- 3 Proksch, E.: The role of emollients in the management of diseases with chronic dry skin. *Skin Pharmacol Physiol*, 2008, 21, s. 75–80.
- 4 Meibach, H. I. – Surber, Ch.: *Topical Corticosteroids*. Basel, Karger, 1992.
- 5 Litvik, R.: Tacrolimus v koncentraci 0,03 % a 0,1 % ve formě masti. *Farmakoterapie*, 2008, s. 5–10.
- 6 Simpson, E. L. – Hanifin, J. M.: Atopic dermatitis. *J Am Acad Dermatol*, 2005, 53, s. 115–128.
- 7 Hanifin, J. M. – Cooper, K. D., et al.: Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". *J Am Acad Dermatol*, 2004, 50, s. 391–404.
- 8 Jung, T. – Stingl, G.: Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. *J Allergy Clin Immunol*, 2008, 122, s. 1074–1081.
- 9 Benáková, N.: Atopická dermatitida. In: *Léčba atopické dermatitidy v novém miléniu*. Praha, Astellas Pharma, 2005, s. 3–6.
- 10 Polášková, S.: Proč může selhat léčba u dětí s atopickou dermatitidou. *Farmakoterapie*, 2008, s. 32–35.
- 11 Barbaud, A., et al.: Interest in an emollient containing pentyl rhamnoside in the management of xerosis and atopic skin. *Cosmetic Dermatology*, 2008, 21, s. 647–651.
- 12 Cork, M. J., et al.: *J Allergy Clin Immunol*, 2006, 118, s. 3–21.
- 13 Leung, D. Y. M. – Soter, N. A.: *J Am Acad Dermatol*, 2001, 44 (dopl.), s. S1–12.
- 14 Cork, M., et al.: *Dermatology Update*. Montreal, Kanada, 6.–7. 11. 2003.
- 15 ISAAC Steering Committee: *Lancet*, 1998, 351, s. 1225–1232.
- 16 Bieber, T.: *N Engl J Med*, 2008, 358, s. 1483–1494.
- 17 Beattie, P. E. – Lewis-Jones, M. S.: *Br J Dermatol*, 2006, 155, s. 145–151.
- 18 Spengel, J. M.: *Am J Clin Dermatol*, 2008, 9, s. 233–244.
- 19 Cork, M. J., et al.: Epidermal barrier dysfunction in atopic dermatitis. In: Rawlings, A. V. – Leyden, J. J. (eds.): *Skin Moisturization*. London, Informa Healthcare, 2009 (v tisku).

## Role vitaminu D u chronických zánětlivých onemocnění

MUDr. Jana Čepová, Ph.D., MBA | MUDr. Margareta Beyerová |

Ing. Eva Klapková, Ph.D. | Ing. Marta Pechová | prof. MUDr. Richard Průša, CSc.

Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha

- 1 Nevorál, J.: Cílený screening celiakie. *Postgraduální medicína*, 2010, 76, s. 452.
- 2 Kohout, P.: Celiakie. *Postgraduální medicína*, 2010, 82, s. 463–477.
- 3 Novotná, B.: Vitamin D – imunita, alergie a astma. *Medical Tribune*, 2012, 5.
- 4 Krejsek, J. – Kopecký, O.: *Klinická imunologie*. NUCLEUS HK, 2004.
- 5 Holick, M. F.: *The Vitamin D solution*. Hudson Street Press, USA, 2011.
- 6 Holick, M. F.: Vitamin D Deficiency. *New Engl J Med*, 2007, 357, s. 266–281.
- 7 IOF Releases New Position Statement on Vitamin D Recommendations for Older Adults, Florencie, 2010, [www.nutritionhorizon.com](http://www.nutritionhorizon.com).
- 8 Čepová, J. – Kolářová, J. – Pechová, M. – Kotaška, K. – Průša, R.: Kazuistiky z osteologické ambulance. *Interní medicína pro praxi*, 2012, 14, 2, s. 78–80.
- 9 Čepová, J. – Pechová, M. – Beyerová, M.: Kazuistiky z osteologické ambulance. *Farmakoterapie – klinická praxe*, 2012, 8.
- 10 Brouwer-Brolsma, E. M. – Bischoff-Ferrari, H. A., et al.: Vitamin D: do we get enough? *Osteoporosis Int*, 2012, s00198-012-2231-3.
- 11 Palička, V.: Vitamin D a jeho role (nejen) v osteologii. *Interní medicína pro praxi*, 2011, 13 (10), s. 383–387.
- 12 Raška, I.: Vitamin D v prevenci onemocnění? *Medicína po promoci*, 2012, 4.
- 13 Kvapil, M.: *Diabetologie 2012*. Triton, 2012.
- 14 Čepová, J.: Vitamin D ve zdraví a nemoci, 13. Bergmeyerova konference. *Labor Aktuell*, 2012, 2.

## Doporučené postupy v léčbě astmatu bronchiale

MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha

- 1 Global Initiative for Asthma (GINA). *GINA workshop report: Global strategy for asthma management and prevention*. <http://www.ginasthma.com>.
- 2 Banks, E. D. – Jalloul, A.: Occupational asthma, work-related asthma and reactive airways dysfunction syndrome. *Curr Opin Pulm Med*, 2007, 13, s. 131–136.
- 3 Wenzel, S. E. – Covar, R.: Update in asthma 2005. *Am J Respir Crit Care Med*, 2006, 173, s. 698–706.
- 4 Turner, S.: Exhaled nitric oxide in the diagnosis and management of asthma. *Curr Opin Allergy Clin Immunol*, 2008, 8, s. 70–76.
- 5 Michils, A. – Baldassarre, S. – Van Muylem, A.: Exhaled nitric oxide and asthma kontrol: A longitudinal study in unselected patients. *Eur Respir J*, 2008, 31, s. 539–546.
- 6 Sutherland, E. R. – Martin, R. J.: Asthma and Atypical Bacterial Infection. *Chest*, 2007, 132, s. 1962–1966.
- 7 Moore, W. C. – Peters, S. P.: Update in Astma 2006. *Am J Respir Crit Care Med*, 2007, 175, s. 649–654.
- 8 Tamesis, G. P. – Krawiec, M. E.: Heterogeneity in response to asthma medications. *Curr Opin Allergy Clin Immunol*, 2007, 7, s. 185–189.
- 9 Holgate, S. – Casale, T. – Wenzel, S. – Bousquet, J. – Deniz, Y. – Reischer, C.: The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. *J Allergy Clin Immunol*, 2005, 115, s. 459–465.
- 11 Aubier, M. – Buhl, R. – Ekstrom, T. – Ostinelli, J. – van Schayck, C.P. – Selroos, O. – Haughney, J.: Comparison of two twice-daily doses of



budesonide/formoterol maintenance and reliever therapy. *Eur Respir J*, 2010, 36, s. 524–530.

- 11 Kašák, V.: Kontrola astmatu a exacerbací. *Medicína pro praxi*, 2010, 11, s. 69–73.
- 12 Ekerljung, L. – Bossios, A. – Lotvall, J. – Olin, A. C. – Ronmark, E.: Multi-symptom asthma as an indication of disease severity in epidemiology. *Eur Respir J*, 2011, 38, s. 825–832.
- 13 Pauk, N.: Současný pohled na postavení LABA v terapii astmatu. *Farmakoterapie*, 2010, 6, s. 449–452.

## Rinosinusitidy: od praktického lékaře do specializované péče ORL nebo alergologie?

MUDr. Jan Pokorný, CSc. DG Centrum Ostrava, ORL

- 1 Markalous, B. – Charvát, F., et al.: *Zobrazení hlavy*. Triton, 2006, 658 s.
- 2 Kuchynková, Z.: *Nosní polypy*. Galén, 2003, 100 s.

## Využití salinických roztoků v léčbě onemocnění horních cest dýchacích

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 2. a 3. LF UK, Praha

- 1 Middleton, P. G. – Pollard, K. A. – Wheatley, J. R.: Hypertonic saline alters ion transport across the human airway epithelium. *Eur Respir J*, 2001, 17, s. 195–199.
- 2 Talbot, A. R. – Herr, T. M. – Parsons, D. S.: Mucociliary clearance and buffered hypertonic saline solution. *Laryngoscope*, 1997, 107, s. 500–503.
- 3 Greiff, L. – Andersson, M. – Wollmer, P. – Persson, C. G.: Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo. *Eur Respir J*, 2003, 21, s. 308–312.
- 4 Kim, C. H. – Hyun, S. M. – Eun, A. Y. – Lee, J. G. – Yoon, J. H.: Effect of hypo-, iso- and hypertonic saline irrigation on secretory mucins and morphology of cultured human nasal epithelial cells. *Acta Otolaryngol*, 2005, 125, s. 1296–1300.
- 5 Kim, J. Y. – Hong, Y. S. – Choi, S. H. – Yoon, Y. H. – Moon, S. W. – Lee, S. W.: Effect of hypertonic saline on apoptosis of polymorphonuclear cells. *J Surg Res*, 2012, 178, s. 401–408.
- 6 Han, C. – Choi, S. H. – Yoon, Y. H., et al.: Hypertonic saline downregulate the production level of lipopolysaccharide-induced migration inhibitory factor in THP-1 cells. *J Korean Surg Soc*, 2012, 82, s. 1–7.
- 7 Garavello, W. – Romagnoli, M. – Sordo, L. – Gaini, R. M. – Di Berardino, C. – Angrisano, A.: Hypersaline nasal irrigation in children with symptomatic seasonal allergic rhinitis: A randomized study. *Pediatr Allergy Immunol*, 2003, 14, s. 140–143.
- 8 Garavello, W. – Romagnoli, M. – Gaini, R. M.: Hypertonic or isotonic saline for allergic rhinitis in children. *Pediatr Allergy Immunol*, 2005, 16, s. 91–92.
- 9 Shoseyov, D. – Bibi, H. – Shai, P. – Shoseyov, N. – Shazberg, G. – Hurvitz, H.: Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis. *J Allergy Clin Immunol*, 1998, 101, s. 602–605.
- 10 Taccariello, M. – Parikh, A. – Darby, Y. – Scadding, G.: Nasal douching as a valuable adjunct in the management of chronic rhinosinusitis. *Rhinology*, 1999, 37, s. 29–32.
- 11 Rabago, D. – Pasic, T. – Zgierska, A. – Mundt, M. – Barrett, B. – Mabberry, R.: The efficacy of hypertonic saline nasal irrigation for chronic sinonasal symptoms. *Otolaryngol Head Neck Surg*, 2005, 133, s. 3–8.
- 12 Adappa, N. D. – Wei, C. C. – Palmer, J. N.: Nasal irrigation with or without drugs: the evidence. *Curr Opin Otolaryngol Head Neck Surg*, 2012, 20, s. 53–57.
- 13 Harvey, R. – Hannan, S. A. – Badia, L. – Scadding, G.: Nasal saline irrigations for the symptoms of chronic rhinosinusitis. *Cochrane Database Syst Rev*, 2007, CD006394.
- 14 Friedman, M. – Hamilton, C. – Samuelson, C. G., et al.: Dead Sea salt irrigations vs saline irrigations with nasal steroids for symptomatic treatment of chronic rhinosinusitis: A randomized, prospective double-blind study. *Int Forum Allergy Rhinol*, 2012, 2, s. 252–257.
- 15 Rabago, D. – Zgierska, A.: Saline nasal irrigation for upper respiratory conditions. *Am Fam Physician*, 2009, 80, s. 1117–1119.

## Kardiovaskulární bezpečnost indakaterolu v léčbě chronické obstrukční plicní nemoci

Prim. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie Nemocnice Na Bulovce a 3. LF UK Praha

- 1 Kašák, V.: Indacaterol – první inhalační  $\beta_2$ -agonista s ultradlouhodobým účinkem (ultra-LABA) pro léčbu CHOPN. *Farmakoterapie*, 2010, 6, 1, s. 40–49.
- 2 Zindr, V.: Bezpečnost indakaterolu v ročních studiích. *Stud Pneumol Phtiseol*, 2011, 71 (4), s. 171–178.
- 3 Khnidri, S. – Sabo, R. – Hartus, S. – Jennings, S. – Drollmann, A. F.: A thorough QT study on the effect of indacaterol on cardiac safety in healthy subjects. *Am J Respir Crit Care Med*, 2009, 179, A2463.
- 4 Chapman, K. R. – Rennard, S. I. – Dogra, A. – Owen, R. – Larsen, C. – Kamer, B.: Long-term safety and efficacy of indacaterol, a novel long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. *Chest*, 2011, 140 (1), s. 68–75.
- 5 Dahl, R. – Chung, K. F. – Buhl, R., et al.: Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. *Thorax*, 2010, 65, s. 473–479.
- 7 Buhl, R. – Dunn, L. J. – Disdier, C. – Larsen, C. – Amos, C. – Henley,

M. – Kamer, B.: *Eur Respir J*, 201, 38, s. 797–803.

8 Donohue, J. F. – Fogarty, C. – Lotvall, J., et al.: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. *Am J Respir Crit Care Med*, 2010, 182, s. 155–162.

9 Worth, H. – Chung, K. F. – Felser, J. M. – Hu, H. – Rueegg, P.: Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. *Respiratory Medicine*, 2011, 105, s. 571–579.

## Novinky v léčbě karcinomu plic

prof. MUDr. Jana Skříčková, CSc. | MUDr. Marcela Tomíšková | MUDr. Bohdan Kadlec | MUDr. Lenka Jakubíková, Ph.D. | MUDr. Jana Špaldová  
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno  
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz LF a PF MU Brno

- Bonomi, P.: Clinical studies with non-irreversible EGFR tyrosine kinase inhibitors. *Lung Cancer*, 2003, 41, s. 43–48.
- Cappuzzo, F. – Ciuleanu, T. – Stelmakh, L., et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol*, 2010, 11, s. 521–529.
- Ciuleanu, T. – Brodowicz, T. – Zielinski, C., et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. *Lancet*, 2009, 374, s. 1432–1440.
- Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New England Journal of Medicine*, 2009, 361, s. 947–957.
- Giroux, D. J. – Rami-Porta, R. – Chansky, K., et al.: The IASLC Lung Cancer Staging Project: data elements for the prospective project. *J Thorac Oncol*, 2009, 4, s. 679–683.
- Cheng, S. – Evans, W. K. – Stys-Norman, D. – Shepherd, F. A.: Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. *J Thorac Oncol*, 2007, 2, s. 348–354.
- Kim, E. S. – Hirsch, V. – Mok, T., et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III trial (INTEREST). *Lancet*, 2008, 372, s. 1809–1818.
- Kwak, E. L. – Bang, Y. J. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.
- Lynch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, 2004, 350, s. 2129–2139.
- Miller, V. A. – O'Connor, P. – Soh, C., et al.: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2009, 27, s. 18.
- Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell lung cancer. *J Thorac Oncol*, 2006, 1, s. 270–278.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): nonsmall cell lung cancer, verze 2. 2012 [online]. Dostupné z: [www.nccn.com](http://www.nccn.com) [vyhledáno 20. 10. 2011].
- NCCN Clinical Practice Guidelines in Oncology: Small cell lung cancer. NCCN National Comprehensive Cancer Network, verze 1. 2008, 2007, [www.nccn.org](http://www.nccn.org), 24–25.
- Niho, S. – Kubota, K. – Yoh, K., et al.: Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. *J Thorac Oncol*, 2008, 3, s. 723–727.
- Patel, S. – MacDonald, O. K. – Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. *Cancer*, 2009, 115, s. 842–850.
- Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*, 2012, 13, s. 247–255.
- Pešek, M., et al.: *Bronchogenní karcinom*. Praha, Galén, 2002.
- Pešek, M. – Skříčková, J. – Kolek, V., et al.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. *Stud Pneumol Ftiseol*, 2009, 69, s. 62–68.
- Pešek, M.: *Nemalobuněčný karcin plic*. EUNL. <http://www.euni.cz/tema.php?>
- Pijls-Johannesma, M. – De Ruyscher, D. – Vansteenkiste, J., et al.: Timing of chemoradiotherapy in patients with limited stage small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. *Cancer Treat Rev*, 2007, 33, s. 461–473.
- Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 1227–1234.
- Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for advanced non-small-cell lung cancer. *Eur Respir J*, 2009, 33, s. 915–930.
- Shaw, A. T. – Yeap, B. Y. – Solomon, B., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*, 2011, 12, s. 1004–1012.
- Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. *J Clin Oncol*, 1988, 6, s. 832–838.
- Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
- Schneider, B. J.: Management of recurrent small cell lung cancer. *J Natl Compr Canc Netw*, 2008, 6, s. 323–331.
- Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small-cell lung cancer. *Crit Rev Oncol Hematol*, 2004, 49, s. 119–133.
- Skříčková, J. – Kolek, V., et al.: *Základy moderní pneumoonkologie*. Maxdorf, Praha, 2012, s. 490.
- Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- Soda, M. – Takada, S. – Takeuchi, K., et al.: A mouse model for EML4-ALK-positive lung cancer. *Proc Natl Acad Sci USA*, 2008, 105, s. 19893–19897.
- Wong, D. W. – Leung, E. L. – So, K. K., et al.: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*, 2009, 115, s. 1723–1733.
- Yang, J. CH. – Schuler, M. – Yamamoto, N. – O'Byrne, K. – Hirsh, V. – Tony Mok, T., et al.: LUX-Lung 3: a randomized, open-label, Phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30 (dopl.; abstrakt LBA7500).
- Zatloukal, P. – Petruželka, L.: *Karcinom plic*. Praha, Grada, 2001.

# Chronická obstrukční plicní nemoc

MUDr. Lucie Cwíková Městská nemocnice Ostrava-Fifejdy

- 1 Kolek, V. – Kašák, V. – Vašáková, M.: *Pneumologie*. Maxdorf, 2011, s. 552.

## Flutikazon furoát v léčbě alergické rýmy

MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň

- 1 Strachan, D. – Sibbald, B., et al.: Worldwide variation of prevalence of symptoms of allergic rhinoconjunctivitis in children (ISAAC). *Pediatr Allergy Immunol*, 1997, 8, s. 161–176.
- 2 Bousquet, et al.: ARIA 2008 Update. *Allergy*, 2008, 63, s. 8–160.
- 3 Salter, M., et al.: *GW685698-enhanced affinity for glucocorticoid receptor: cellular and in vivo pharmacology*, prezentováno na: XXV Congress of EAACI, Vína, 2006, abstrakt 781.
- 4 Salter, M., et al.: *Fluticasone furoate-enhanced cellular and tissue protection with a new selective glucocorticoid antagonist*. AAACI, Philadelphia, 2006.
- 5 Allen, A., et al.: *Tolerability, safety and pharmacokinetics and bioavailability of INSFF in healthy subjects*. ACAAI, Philadelphia, 2006.
- 6 Fuad, M. – Kimberly, A., et al.: Nasal ocular reflex and eye symptoms in patients with allergic rhinitis. *Ann Allergy Asthma Immunol*, 2008, 100, s. 194–199.

## Léčba pacienta IFN- $\beta$ -1b (Betaferonem)

MUDr. Magdaléna Hladíková, Ph.D. Neurologická klinika LF MU a FN Brno

- 1 Mendes, A. – Sá, M. J.: Classical immunomodulatory therapy in multiple sclerosis: How it acts, how it works. *Arq Neuropsiquiatr*, 2011, 69, s. 536–543.
- 2 The IFN- $\beta$  Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology*, 1993, 43, s. 655–661.
- 3 European Study Group on Interferon  $\beta$ -1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. *Lancet*, 1998, 3523, s. 1491–1497.
- 4 Kappos, L. – Polman, C. H., et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, 2006, 67, s. 1242–1249.
- 5 Kappos, L. – Freedman, M. S., et al.: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year followup analysis of the BENEFIT study. *Lancet*, 2007, 370, s. 389–397.
- 6 Edan, G. – Kappos, L., et al.: Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial. *Mult Scler*, 2011, 10 (dopl.).
- 7 Durelli, L. – Verdun, E., et al.: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). *Lancet*, 2002, 359, s. 1453–1460.
- 8 O'Connor, P. – Filippi, M., et al.: 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol*, 2009, 8, s. 889–897.
- 9 Cadavid, D. – Wolansky, L. J., et al.: Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. *Neurology*, 2009, 72, s. 1976–1983.
- 10 Polman, C. H. – Bertolotto, A., et al.: Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. *Lancet Neurol*, 2010, 9, s. 740–750.

## Využití certolizumab pegolu v léčbě aktivní revmatoidní artritidy

MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň

- 1 Venkovský, J.: Certolizumab pegol v léčbě revmatoidní artritidy. *Re-media*, 2009, 19, s. 308–311.
- 2 Zeman, J.: Certolizumab a léčba revmatoidní artritidy. *Klin Farmakol Farm*, 2011, 25, s. 76–78.
- 3 Strojil, J. – Ciferská, H.: Certolizumab pegol. *Klin Farmakol Farm*, 2010, 24, s. 155–160.
- 4 Fleischmann, R. – Vencovsky, J. – van Vollenhoven, R. F., et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis*, 2009, 68, s. 805–811.
- 5 Keystone, E. C. – Fleischmann, R. – Smolen, J., et al.: Sustained efficacy of certolizumab pegol added to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA): 2-year results from the RAPID 1 trial. *Ann Rheum Dis*, 2009, 68, s. 237.
- 6 Smolen, J. – Landewé, R. B. – Mease, P., et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis*, 2009, 68, s. 797–804.
- 7 Olejárová, M.: Bezpečnost a účinnost certolizumab pegolu v léčbě revmatoidní artritidy. *Farmakoterapie*, 2011, 7, s. 335–341.
- 8 Mariette, X. – van Vollenhoven, R. F. – Bykerk, V. P., et al.: Safety update on certolizumab pegol in patients with active RA with long term exposure. *Arthritis Rheum*, 2012, 10, s. 221.

# Účinná léčba abataceptem v první linii u pacientky s diabetem mellitem I. typu a s revmatoidní artritidou

MUDr. Petr Kopsa Revmatologické a rehabilitační oddělení Thomayerovy nemocnice, Praha

- 1 Schiff, M. – Bessete, L., et al.: Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. *Clin Rheumatol*, 2010, 29, s. 583–591.
- 2 Weinblatt, M. – Combe, B., et al.: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs. *Arthritis & Rheumatism*, 2006, 54, s. 2807–2816.
- 3 Schiff, M. – Keiseman, M. – Codding, C., et al.: Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. *Ann Rheum Dis*, 2011, 70, s. 2003–2007.
- 4 Kremer, J. M. – Russell, A. S., et al.: Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. *Ann Rheum Dis*, 2011, 70, s. 1826–1830.
- 5 Orban, T. – Bundy, B., et al.: Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. *Lancet*, 2011, doi: 10.1016/S0140-6736(11)60886-6.

## Subkutánní interferon beta-1a v léčbě roztroušené sklerózy

MUDr. Iva Okáčová | doc. MUDr. Pavel Štourač, Ph.D. Neurologická klinika LF MU a FN Brno, CEITEC – Středoevropský technologický institut MU Brno

- 1 Havrdová, E., et al.: Roztroušená skleróza. In: *Neuroimunologie*. Maxdorf, 2001, s. 150–151.
- 2 Bednařík, J. – Amber, Z. – Růžička, E., et al.: Roztroušená skleróza. In: *Klinická neurologie, část speciální I*. Triton, 2010, s. 509–510.
- 3 Kappos, L. – Polman, C. H. – Freedman, M. S., et al.: Treatment with interferon b-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. *Neurology*, 2006, 67, s. 1242–1249.
- 4 Štourač, P.: Imunomodulační léčba roztroušené sklerózy mozkomíšní v klinických a zobrazovacích parametrech. *Cesk Slov Neurol N*, 2012, 75, s. 404–410.
- 5 Horáková, D.: Klinicky izolovaný syndrom a prognostické markery u roztroušené sklerózy. Proč léčit včas? *Neurol. pro praxi*, 2008, 9, s. 215–217.
- 6 Havrdová, E.: Roztroušená skleróza. *Cesk a Slov Neurol Neurochir*, 2008, 71, s. 121–132.
- 7 The IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNβ Multiple Sclerosis Study Group. *Neurology*, 1993, 43, s. 655–661.
- 8 Jacobs, L. D. – Cookfair, D. L. – Rudick, R. A., et al.: Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. *Ann Neurol*, 1996, 39, s. 285–294.
- 9 PRISMS study group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by interferon β-1a in Subcutaneously in Multiple Sclerosis) Study Group. *Lancet*, 1998, 352, s. 1498–1504.
- 10 Jacobs, L. D. – Beck, R. W. – Simon, J. H., et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. *N Eng J Med*, 2000, 343, s. 898–904.
- 11 Comi, G. – Filippi, M. – Barkhof, F., et al.: Effect of early treatment on conversion to definite multiple sclerosis: A randomized study. *Lancet*, 2001, 357, s. 1576–1582.
- 12 Horáková, D.: Léčba klinicky izolovaného syndromu a remitentní roztroušené sklerózy – aktuální doporučení zohledňující nové etiopatogenetické poznatky. *Neurol pro praxi*, 2010, 13, s. 8–11.
- 13 Kappos, L. – Freedman, M. S. – Polman, C. H. – Edan, G. – Hartung, H. P. – Miller, D. H. – Montalbán, X. – Barkhof, F. – Radu, E. W. – Metz, C. – Bauer, L. – Lanius, V. – Sandbrink, R. – Pohl, C. – BENEFIT Study Group: Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol*, 2009, 8, s. 987–997.
- 14 Souhrn údajů o přípravku, SUKL, Interferon beta-1a, [http://www.ema.europa.eu/docs/cs\\_CZ/document\\_library/EPAR\\_-\\_Product\\_Information/human/000136/WC500048681.pdf](http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf), vyhledáno dne 14. 12. 2012.
- 15 Cohen, J. A. – Barkhof, M. – Comi, G. – Hartung, H. P. – Khatri, B. – Montalban, X., et al.: TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Eng J Med*, 2010, 362, s. 402–415.
- 16 Panitch, H. – Goodin, D. S. – Francis, G. – Chang, P. – Coyle, P. K. – O'Connor, P., et al.: Randomized comparative study of interferon beta 1a treatment regimen in MS: the EVIDENCE trial. *Neurology*, 2002, 59, s. 1496–1506.

## Systemová léčba osteolýzy indukované nádorem

MUDr. Simona Paulíková | prof. MUDr. Jiří Petera Ph.D. | MUDr. Adam Paulík  
LF UK a Klinika onkologie a radioterapie FN Hradec Králové

- 1 Coleman, R. E.: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. *Cancer Treat Rev*, 2001, 27, s. 165–176.
- 2 Wardley, A. M.: Bone disease in cancer: a growing health problem. In: *Bone disease in cancer. Abstract book of the congress*. Itálie, Benátky, 24.–25. 6. 2006.
- 3 Holubec, L. – Matějka, V. M.: Význam PET/CT pro diagnostiku a kontrolu léčby nemocných s kostními metastázami z pohledu klinické onkologie. *Edukační sborník XXXV. Brněnských onkologických dní*, 2011, s. 263–264.
- 4 Kolář, J.: Metastázy do skeletu. *Radiodiagnostika*, 2005, svazek 51, č. 6.



- 5 **Křístek, J.:** Perkutánní cementoplastika osteolytických metastáz do skeletu. *Edukační sborník XXXV. Brněnských onkologických dní*, 2011, s. 265–266.
- 6 **Hortobagyi, G. N.:** Novel approaches to the management of bone metastase. *Semin Oncol*, 2003, 30 (dopl. 16), s. 161–166.
- 7 **Hortobagyi, G. N.:** Treatment of breast cancer. *N Engl J Med*, 1998, 339, s. 974–984.
- 8 **Fleisch, H.:** Bisphosphonates: A new class drug in disease of bone and calcium metabolism. In: Brunner, K. W. – Fleisch, H. – Senn, H. J., eds.: *Bisphosphonates and Tumor Osteolysis*. Německo, Berlín, Springer-Verlag, 1989, s. 1–28.
- 9 **Parker, C. – Heindrich, D. – O'Sullivan, L. M., et al.:** Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastase on castration-resistant prostate cancer: A phase III randomized trial (ALSYMPCA). *ECCO-ESMO*, 2011, abstrakt 1LBA.
- 10 **Barton, M. K.:** Denosumab an option for patients with bone metastasis from breast cancer. *CA Cancer J Clin*, 2011, květen, s. 135–136.

## Antitrombotická léčba – léčba apixabanem

MUDr. Hynek Poul Oddělení hematologie a transfuziologie Nemocnice Pelhřimov, p. o.

- 1 **Ericsson, B. I. – Quinlan, D. J. – Weitz, J. I.:** Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. *Clin Pharmacokinet*, 2009, 48, s. 1–22.
- 2 **Turpie, A. G. G.:** Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. *Arterioscler Thromb Vasc Biol*, 2007, 27, s. 1238–1247.
- 3 **Ansell, J. J.:** Factor Xa or thrombin: is factor Xa a better target? *Thromb Haemost*, 2007, 5, s. 60–64.
- 4 **Larsen, M. R., et al.:** APROPOS=Apixaban PROphylaxis in Patients undergoing total knee replacement Surgery. *J Thromb Haemost*, 2007, 5, s. 2368–2375.
- 5 SPC Eliquis.
- 6 **Raskob, G. E. – Gallus, A. S. – Pineo, G. F. – Chen, D. – Ramirez, L. M. – Wright, R. T. – Larsen, M. R.:** Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. *J Bone Joint Surg Br*, 2012, 94, s. 257–264.
- 7 **Wang et al.:** Prezentováno na WCCPT 2008. Poster T2TH071.
- 8 **Barrett, Y. C. – Wang, Z. – Frost, C. – Shenker, A.:** Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. *Thromb Haemost*, 2010, 104, s. 1263–1271.
- 9 **Gogarten, W., et al.:** Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. *Eur J Anaesthesiol*, 2010, 27, s. 999–1015.
- 10 **Eikelboom, J. W. – O'Donnell, M. – Yusuf, S. – Diaz, R. – Flaker, G. – Hart, R. – Hohnloser, S. – Joyner, C. – Lawrence, J. – Pais, P. – Pogue, J. – Synhorst, D. – Connolly, S. J.:** Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. *Am Heart J*, 2010, 159, s. 348–353.
- 11 **Yates, S. W.:** Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence. *Hosp Pract (Minneapolis)*, 2011, 39, s. 7–16.
- 12 **Granger, C. B.:** ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2011, 15, 365, s. 981–992.
- 13 **Wong, P. C. – Pinto, D. J. P. – Zhang, D.:** Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. *J Thromb Thrombolysis*, 2011, 31, s. 478–492. Publikováno on-line 13. 2. 2011, doi: 10.1007/s11239-011-0551-3.

## Novinky ve fekální bakterioterapii

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 **Eiseman, B. – Silen, W. – Bascom, G. S. – Kauvar, A. J.:** Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. *Surgery*, 1958, 44, s. 854–859.
- 2 **Kelly, C. P. – LaMont, J. T.:** Clostridium difficile – more difficult than ever. *NEJM*, 2008, 359, s. 1932–1940.
- 3 **Gough, E. – Shaikh, H. – Magnes, A. R.:** Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. *Clinical Infectious Diseases*, 2011, 53, s. 994–1002.
- 4 **Kelly, C. P.:** Fecal microbiota transplantation – an old therapy comes of age. *NEJM*, 2013, publikováno před tiskem, doi: 10.1056/NEJMe1214816.
- 5 **van Nood, E. – Vrieze, A. – Nieuwdorp, M. – Fuentes, S. – Zoetendal, E. G. – de Vos, W. M. – Visser, C. E. – Kuijper, E. J. – Bartelsman, J. F. W. M. – Tijssen, J. G. P. – Speelman, P. – Dijkgraaf, M. G. W. – Keller, J. J.:** Duodenal infusion of donor feces for recurrent Clostridium difficile. *NEJM*, 2013, publikováno před tiskem, doi: 10.1056/NEJMoa1205037.
- 6 **Petrof, E. O. – Gloor, G. – Vanner, S. J. – Weese, S. J. – Carter, D. – Daig-neault, M. C. – Brown, E. M. – Schroeter, K. – Allen-Vercoe, E.:** Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut. *Microbiome*, 2013, 1, s. 3.
- 7 **Tvede, M. – Rask-Madsen, J.:** Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. *Lancet*, 1989, 1, s. 1156–1160.
- 8 **Upadhyay, V. – Poroyko, V. – Kim, T. – Devkota, S. – Fu, S. – Liu, D. – Tumanov, A. V. – Koroleva, E. P. – Deng, L. – Nagler, C. – Chang, E. B. – Tang, H. – Fu, Y-X.:** Lymphotoxin regulates commensal responses to enable diet-induced obesity. *Nature Immunology*, 2012, 13, s. 947–953.
- 9 **Smith, M. I. – Yatsunenkov, T. – Manary, M. J. – Trehan, I. – Mkakosya, R. – Cheng, J. – Kau, A. L. – Rich, S. S. – Concannon, P. – Mychaleckyj, J. C. – Liu, J. – Houghton, E. – Li, J. V. – Holmes, E. – Nicholson, J. – Knights, D. – Ursell, L. K. – Knight, R. – Gordon, J. I.:** Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. *Science*, 2013, 339, s. 548–554.
- 10 **Quince, C. – Lundin, E. E. – Andreasson, A. N. – Greco, D. – Rafter, J. – Talley, N. J. – Agreus, L. – Andersson, A. F. – Engstrand, L. – D'Amato, M. I.:** The impact of Crohn's disease genes on healthy human gut microbiota: a pilot study. *Gut*, 2013, publikováno před tiskem, doi:10.1136/gutjnl-2012-304214.